News about

Jefferies Says Analysis on Elan Supports $19/Share Takeover Bid, Lifts Price Target to $19

Tue, 18 Jun 2013 10:39:09 -0400

In a report from Jefferies' Corey Davis published Tuesday, the analyst suggested Elan (NYSE: ELN) execs have indicated they may agree or strongly consider a takeover anywhere between $15 to $20 per share.

Davis's analysis supports a $19/share bid, but only from a "high taxpaying suitor."

Davis named some

Weekly Wrap-Up + Market Forecast + Sector Watch: SPX, Nasdaq, GLD, BTK, XLE, XLF, GS, MA, V, JPM, BAC, APA, APC, HES, OXY, CELG, ONXX, GILD, BIIB, REGN, ALXN

Mon, 17 Jun 2013 00:19:14 -0400

Last weekend, in my Market Forecast, I wrote: "For the new week, stocks may need a little pause and consolidation to start the week. There is resistance between 1650 and 1660. On the down side, we will have to be careful if SPX falls below 1620 again. Techs actually held up surprisingly well. But, biotechs [...]

Bio-Wire Equity Surveillance – Closing Bell 6/12/2013

Wed, 12 Jun 2013 16:51:03 -0400

Wednesday, June 12th, 2013 DJIA: -.84% to 14,995.23 S&P 500: -.84% to 1,612.52 NASDAQ: -1.06% to 3,400.43 NYSE Arca – Pharma Index: -.06% to 425.42 Big pharma (Mkt Cap $10 B+) -.89% Mid-sized pharma ($2-10 B) -.90% Small pharma ($300 M to $2 B) -.99% Micro pharma (<$300M) -.23% Notable Jumps by % Gain and Mkt Cap Change Questcor Pharmaceuticals (NASDAQ: QCOR) +7.38% to [...]

Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Wed, 12 Jun 2013 13:29:25 -0400

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates.

The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ:

Positive Data on Bayer/REGN’s Eye Drug – Analyst Blog

Fri, 07 Jun 2013 17:15:01 -0400

Bayer announced positive top-line results from the phase III MYRROR study on VEGF Trap-Eye.

Market Wrap for Thursday, June 6: Stocks Reverse Mid-Day; Rally to Close at Session Highs

Thu, 06 Jun 2013 16:33:20 -0400

The U.S. stock market surged on Thursday after an afternoon rally lifted the major averages out of negative territory.

Stocks closed near their best levels of the session, with the Dow adding around 80 points. Around mid-day, the market appeared to be in danger of adding to its recent losses,

Bio-Wire Equity Surveillance – Closing Bell 6/6/2013

Thu, 06 Jun 2013 16:29:15 -0400

Thursday, June 6th, 2013 Overview Today was bullish (after a reversal) for the broader market with the Dow moving +.53% to 15,041, the S&P 500 moving +.57% to 1618 and the NASDAQ moving +.66% to 3424. Big pharma companies (Mkt Cap $10 B+) gained +1.6% on average, mid-sized pharma ($2-10 B) gained +1.7% as a whole, the average small pharma [...]

Just A Healthy Pullback? CELG, VIX, DDD, XPY, GS, C, PNC, V, BIIB, CELG, REGN

Thu, 06 Jun 2013 01:12:16 -0400

Markets struggled to find a direction on Monday. But, today, dip-buyers shied away from buying. Stocks were mostly lower. We locked in gains on our downside trades, including a +204% profit on CELG puts: 12:34 | HappyTrading CELG ($112.50) Sold to Close 06P120 Jun 120 put, at $8.50 +204% 08:09 | HappyTrading CELG ($155.80) Sold [...]

CHMP Positive on Aegerion’s Lojuxta – Analyst Blog

Mon, 03 Jun 2013 18:30:01 -0400

Aegerion Pharmaceuticals, Inc. received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lojuxta (lomitapide)

3 ways to play the biotech boom

Mon, 03 Jun 2013 07:00:58 -0400

If you want to join in the biotech boom, these funds offer varying levels of risk and protection, writes Jeff Reeves.

Market Forecast + Sector Watch: SPX, Nasdaq, FDN, BTK, XRT, XLE, APC, OXY, IOC, SLB, RIG, DO, KORS, ANF, SHLD, LULU, BIIB, CELG, REGN, ALXN, AMZN, GOOG, PCLN

Mon, 03 Jun 2013 00:44:37 -0400

Last weekend, in my Market Forecast, we discussed: "For the new week, major sectors are testing supports. I think we’ll see a range-bound market. SPX now has resistance at 1680 and support between 1640 and 1630. Gold may seen some bounces." Things pretty much happened as forecasted. On Tuesday, stocks popped and SPX ran as [...]

Short Interest in Vertex Rises, in Biogen Idec Falls

Wed, 29 May 2013 13:19:27 -0400

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates.

The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena

Short Interest in Vertex Rises, in Celgene Falls

Sat, 11 May 2013 10:45:31 -0400

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April.

The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ:

Midcaps Double S&P 500 Return: Get the Right ETF

Tue, 07 May 2013 09:00:13 -0400

UPDATE: Jefferies Raises PT on Regeneron Pharmaceuticals Following Top-Line Q1 Beat

Mon, 06 May 2013 12:50:11 -0400

In a report published Monday, Jefferies analyst Biren Arnin reiterated a Hold rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $179.00 to $247.00.

In the report, Arnin noted, “REGN reported a top-line beat driven by U.S. Eylea sales leading to slightly raised guidance. Given the

Bio-Wire Weekly: April 29 – May 3rd, 2013

Mon, 06 May 2013 12:43:43 -0400

Bio-Wire Weekly: April 29 – May 3rd, 2013 To get this email earlier, sign up for our email list The Newsmakers: 1.) Auxilium Pharmaceuticals (NASDAQ: AUXL) Auxilium Pharma was down about 8% in the last week after the company released Q1 2013 earnings on Monday, April 29th (press release) as well as a corporate update in which [...]

Regeneron Study: EYLEA Growth Potential

Mon, 06 May 2013 06:37:30 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) has received an immense amount of attention in the past year, and has doubled the wealth of shareholders primarily due to the shockingly good performance of the VEGF inhibitor EYLEA (Aflibercept) in the wet AMD indication – particular in Q1 2013 (or Q4 2012 fiscally, for the company). The company reported [...]

Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data

Fri, 03 May 2013 16:28:54 -0400

The U.S. stock market jumped on Friday to end the trading week. The catalyst for the move higher was a strong jobs report, which briefly sent the Dow Jones Industrial Average over 15,000 for the first time in history.

Heading into next week, the markets will be sitting at new year-to-date

Eylea Drives Earnings at Regeneron – Analyst Blog

Fri, 03 May 2013 14:39:01 -0400

Regeneron reported higher than expected earnings in the first quarter of 2013.

Friday’s movers: LinkedIn, Delcath Systems

Fri, 03 May 2013 08:22:05 -0400

Shares of Regeneron Pharmaceuticals led the S&P 500 in premarket trade on Friday while LinkedIn Corp. and Delcath Systems shares fell. Warren Buffett’s Berkshire Hathaway dominated investor attention.

A Peek Into The Market Before The Trading Starts

Fri, 03 May 2013 07:06:04 -0400

Pre-open movers US stock futures are slightly lower this morning, as investors are awaiting nonfarm payrolls. Futures for the Dow Jones Industrial Average dropped 8 points to 14,752.00 and S&P 500 index futures fell 1.50 points to 1,590.80. Nasdaq 100 futures declined 0.75 points to 2,901.25.

A Peek Into Global Markets European

Regeneron Acquires Rights to Two Families of Novel Antibodies

Fri, 03 May 2013 06:41:23 -0400

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi. Regeneron acquired full rights to antibodies targeting the PDGF (platelet derived

Regeneron Pharmaceuticals: The Stock That Only Goes Up?

Wed, 01 May 2013 16:42:13 -0400

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were trading at new all-time high levels on Wednesday afternoon on concerns that rival Allergan (NYSE: AGN) may have problems moving its unnamed vision-loss drug into late-stage trials.

The speculation is that Allergan believes it may have trouble getting its

Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April

Wed, 01 May 2013 16:16:23 -0400

The U.S. stock market was hit hard on Wednesday as investors reacted to a report which showed slowing employment conditions for the month of April.

The losses were also likely amplified by profit taking as the Dow and S&P have been hovering near record highs in recent days. Overall, all

UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Cardiologist/Lipidologist Survey

Wed, 01 May 2013 09:35:10 -0400

In a report published Wednesday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $230.00 to $240.00.

In the report, Flynn noted, “We recently conducted a survey of 41 US cardiologists/lipidologists to gauge awareness of the anti-PCSK9 drug

Stocks to Watch for April 30, 2013

Mon, 29 Apr 2013 17:27:00 -0400

Stocks To Watch For April 30, 2013

Mon, 29 Apr 2013 17:27:00 -0400

( click to enlarge ) Research In Motion Ltd (BBRY) had a nice breakout from the symmetrical triangle on solid volume. Upcoming resistance is at 16.01 and 16.82 which are the previous highs. Looking at the technical chart we can see a couple of bullish signals confirming the “breakout” and we can expect the price [...]

Market Forecast + Sector Watch: SPX, Nasdaq, GLD, XME, XLE, BTK, AMGN, BIIB, GILD, REGN, GILD, RIG, SLB, APC, OXY, EOG, CLF, WLT

Mon, 29 Apr 2013 01:26:47 -0400

Last weekend, in my Market Forecat, I said, "This market will need some strong earnings report to bounce back up. SPX 1570 could now become a resistance. The market will need to clear above 1580 to resume its bullish trend. On the downside, if 1540 does not hold, the next support is at 1520. Techs [...]

Short Sellers Move into Celgene, Regeneron

Fri, 26 Apr 2013 13:25:43 -0400

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April.

The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ:

(REGN) Regeneron Pharmaceuticals Rated Neutral Again

Thu, 18 Apr 2013 17:40:10 -0400

We recently maintained our Neutral recommendation on biopharmaceutical company, Regeneron...

Visit StockBlogHub to view complete post.

Market Slumps Back to Test Monday’s Low: SPX, Nasdaq, AAPL, CRUS, BAC, GS, EBAY, SNDK, BIIB, AMGN, CELG, REGN, GILD

Thu, 18 Apr 2013 02:16:00 -0400

It’s been a few very volatile days: a sharp drop on Monday; a vigorous bounce on Tuesday; then, a quick fall back to Monday’s low in the morning today! For now, the sentiment has shifted. Last week’s strong dip-buying seems not to have as much enthusiasm this week. AAPL led the tech’s decline, falling 5.5%. [...]

Market Forecat + Sector Watch: SPX, Nasdaq, XLF, FDN, XRT, BTK, BIIB, CELG, GILD, AMGN, REGN, ROST, PCLN, EBAY, GOOG, YHOOO, WFC JPM, C, GS, BAC, BK, PNC

Mon, 15 Apr 2013 01:46:54 -0400

Last weekend, in my Market Forecast, I wrote: "For the new week, the market starts from a "neutral" position. You might be thinking, "How can it be ‘neutral’? Especially after Friday’s nasty open!" Well, the Nasdaq is definitely weaker. But, the Dow still closed above its daily MAs. SPX is barely below its 20-day MA." [...]

Weekly Wrap-Up April 13, 2013: JOY, HLF, SODA, GLD, FSLR, PCLN, JPM, WFC, BIIB, AMGN, GILD, REGN, INTC, MSFT, IBM, GOOG

Sun, 14 Apr 2013 00:55:38 -0400

Stocks had another amazing week. A non-stop rally that started on Monday took SPX to its new, all-time, record high, hitting 1597.35! Biotechs continued to soar. BIIB, AMGN, GILD, and REGN were just a few that made new all-time highs in the biotech sector! We had some good trades on both sides. SODA calls gave [...]

Regeneron Touches 52-Week High – Analyst Blog

Thu, 11 Apr 2013 17:30:01 -0400

Shares of Regeneron soared to a 52-week high of $201.35 on Apr 10.

Regeneron Rated Neutral Again – Analyst Blog

Wed, 10 Apr 2013 17:57:01 -0400

We recently maintained our Neutral recommendation on Regeneron.

Short Sellers Move Out of Amgen, Celgene, Pharmacyclics

Wed, 10 Apr 2013 13:30:35 -0400

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March.

The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX), Vertex Pharmaceuticals (NASDAQ:

Minyanville's T3 Morning Market Call: Market Once Again Takes Aim at Highs After Swift Snapback

Wed, 10 Apr 2013 10:34:00 -0400

The S&P will have another chance to take out 2013 highs and perhaps the 1576 intraday all-time high today.

Stocks Hitting 52-Week Highs

Tue, 09 Apr 2013 11:17:25 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) shares jumped 1.44% to create a new 52-week high of $191.18. REGN recently announced plans to expand its headquarters and laboratory in Westchester County, New York.

Life Technologies (NASDAQ: LIFE) shares gained 2.31% to touch a new 52-week high of $66.84. LIFE has

Regeneron Aims HQ Expansion – Analyst Blog

Mon, 08 Apr 2013 19:15:01 -0400

Regeneron will expand its corporate headquarters and laboratories in Westchester County, New York.

Minyanville's T3 Morning Market Call: Is Lousy Jobs Report Actually Good News for Market?

Mon, 08 Apr 2013 10:46:00 -0400

Right now it appears that bad news is good news because of the potential for longer-term QE.

Regeneron Pharma to Expand Corporate HQ, Labs in Westchester County

Thu, 04 Apr 2013 09:17:21 -0400

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company will expand the Regeneron corporate headquarters and laboratories in Westchester County and create more than 400 new high-skill jobs.

Today's announcement further cements the reputation of the Hudson Valley as an emerging epicenter for biopharmaceutical growth.

"Today's announcement

Lucrative AMD & DME Markets Attract Wall Street’s Attention

Wed, 03 Apr 2013 04:33:17 -0400

Lucrative AMD & DME Markets Attract Wall Street’s Attention One of the biggest success stories that we’ve seen in the history of recent drug launches was with the AMD (Age-related Macular Degeneration) treatment EYLEA (aflibercept) – the flagship product of its parent company Regeneron Pharmaceuticals (NASDAQ: REGN). Mascular degeneration is a medical condition that results [...]

Weakness in Miners and Refiners Keep a Lid on the Markets: SPX, Nasdaq, WLT, CLF, TSO, VLO, PSX, CF, AGU, MON, AMGN, BIIB, REGN, BMRN, ALXN, CELG, ONXX, HUM, UNH, WLP, AET, AAPL, NFLX, LNKD

Tue, 02 Apr 2013 22:07:59 -0400

Lots of things happening today. Big sector moves! Miners, especial coals, were still very weak. WLT (-7.96%) and CLF (-4.06) just kept tumbling lower. Oil refiners took a big drop today: TSL -3.22%; VLO -5.69%; PSX -3.62%. Agriculture stocks also dropped further: CF -2.05%; AGU -1.2%; MON -1.69%. On the other hand, healthcare and biotech [...]

Volatile Market Renders Trades on Both Sides: SPX, Nasdaq, MNST, FAS, PCLN, AAPL, GOOG, AMGN, REGN, ADBE, WSM, LULU, DSW, FDX, GLD

Tue, 19 Mar 2013 19:51:51 -0400

In my Market Forecast this weekend, I pointed out that SPX has support between 1550 and 1540. Yesterday, SPX came down to test 1550 and closed above; today, SPX tested 1540 then bounced again. Things opened higher this morning, but, selling soon took over. We found some nice intraday trades on both sides. MNST was [...]

Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)

Tue, 12 Mar 2013 13:19:27 -0400

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of February.

The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx

Regeneron to Earn More Royalty – Analyst Blog

Tue, 05 Mar 2013 13:40:01 -0500

Regeneron will earn more royalty following the EU approval of llaris.

Sanofi/REGN Present Dupilumab Data – Analyst Blog

Mon, 04 Mar 2013 16:00:01 -0500

Sanofi and Regeneron Pharmaceuticals presented data from two phase Ib trials evaluating dupilumab.

Sanofi, Regeneron Report Positive Phase 1b Data for Dupilumab in Atopic Dermatitis

Sat, 02 Mar 2013 10:47:53 -0500

Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting

Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)

Thu, 28 Feb 2013 15:13:04 -0500

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of February. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN) and Vertex Pharmaceuticals (NASDAQ: VRTX) grew somewhat between the January

Top Analyst Upgrades and Downgrades (BSFT, DB, EBAY, EIX, FSLR, GRPN, JCP, RHT, REGN, SKS, UBS, VSI, VMW)

Thu, 28 Feb 2013 03:35:00 -0500

DailyFinance.com: These are some of this Thursday's top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Broadsoft Inc. (NASDAQ: BSFT) downgraded after poor expense guidance at Mizuho, Oppenheimer, and boutique Northland ... Read more